Veeva Systems news
The WiseView Research desk's stories that name Veeva Systems, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The VEEV page →
- HeadlineVeeva Systems (VEEV) Stock Dips While Market Gains: Key Facts
- HeadlineVeeva Survives Selling Pressure, Nearing its All-Time High
- HeadlineVeeva Systems (VEEV) Rises Higher Than Market: Key Facts
- HeadlineIs Veeva (VEEV) a Buy as Wall Street Analysts Look Optimistic?
- HeadlineVeeva Systems Inc. (VEEV) is Attracting Investor Attention: Here is What You Should Know
- HeadlineVeeva to Host Virtual Investor Day on November 5, 2026
- HeadlineVEEV Expands IQVIA Partnership With Clinical Operations Software Suite
- HeadlineVeeva Systems (VEEV) Increases Despite Market Slip: Here's What You Need to Know
- HeadlineVeeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms
- HeadlineReasons to Hold Veeva Systems Stock in Your Portfolio for Now
- HeadlineVeeva Summit to Showcase AI Innovations and the Leaders Transforming R&D and Quality
- HeadlineVeeva's DQS Scales Data Automation Across 1,000+ Clinical Studies
- HeadlineEmerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development
- HeadlineVeeva DQS Cleans Data for More Than 1 Million Subjects Across Over 1,000 Studies
- HeadlineVeeva Systems (VEEV) Stock Sinks As Market Gains: What You Should Know
- HeadlineVeeva Systems (VEEV) Stock Declines While Market Improves: Some Information for Investors
- HeadlineServier Adopts Veeva OpenData Globally to Scale AI
- HeadlineBrokers Suggest Investing in Veeva (VEEV): Read This Before Placing a Bet
- CongressRo Khanna bought $1,001 - $15,000 of VEEV
- CongressRob Bresnahan bought $1,001 - $15,000 of VEEV
- CongressRob Bresnahan sold $1,001 - $15,000 of VEEV
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.